JAMA oncology (JAMA Oncol)

Journal PubWeight™ 587.00‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. 2015 10.42
2 The Global Burden of Cancer 2013. 2015 5.93
3 Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. 2015 5.54
4 Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma-Reply. 2017 5.03
5 Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma. 2017 5.03
6 Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. 2016 4.90
7 Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. 2015 4.16
8 Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. 2015 3.92
9 Patient Perception of Physician Compassion After a More Optimistic vs a Less Optimistic Message: A Randomized Clinical Trial. 2015 3.89
10 Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. 2015 3.64
11 Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. 2016 3.48
12 Patient Demands and Requests for Cancer Tests and Treatments. 2015 3.38
13 Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. 2015 3.13
14 Rethinking the Standard for Ductal Carcinoma In Situ Treatment. 2015 3.05
15 Association Between Parkinson Disease and Risk of Cancer in Taiwan. 2015 2.81
16 Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. 2016 2.79
17 Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. 2016 2.78
18 Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. 2016 2.75
19 Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 2015 2.68
20 SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. 2020 2.67
21 Tamoxifen Chemoprevention-End of the Road? 2015 2.67
22 Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil. 2015 2.65
23 Progesterone Exposure and Breast Cancer Risk: Understanding the Biological Roots. 2015 2.62
24 Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. 2016 2.60
25 Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. 2015 2.52
26 Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. 2016 2.47
27 Population-Based Assessment of Determining Treatments for Prostate Cancer. 2015 2.46
28 Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. 2016 2.41
29 Trends in Advance Care Planning in Patients With Cancer: Results From a National Longitudinal Survey. 2015 2.35
30 Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. 2016 2.34
31 Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. 2015 2.32
32 Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States. 2016 2.22
33 Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. 2015 2.21
34 Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. 2015 2.20
35 Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. 2016 2.19
36 Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. 2016 2.17
37 Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. 2015 2.16
38 Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. 2016 2.16
39 Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. 2016 2.14
40 Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era. 2015 2.14
41 Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. 2015 2.09
42 Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2015 2.09
43 The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. 2016 2.09
44 Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. 2015 2.08
45 Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. 2016 2.06
46 Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 2015 2.06
47 Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. 2016 2.06
48 Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. 2016 2.05
49 Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. 2015 2.04
50 Unanswered Questions Concerning Locoregional Irradiation in Breast Cancer. 2016 2.03
Next 50